首页 | 本学科首页   官方微博 | 高级检索  
     

经皮腔内肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的有效性及安全性评估
引用本文:金博文,张刚成,沈群山,龙恺. 经皮腔内肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的有效性及安全性评估[J]. 中华心血管病杂志, 2022, 0(1): 49-54
作者姓名:金博文  张刚成  沈群山  龙恺
作者单位:武汉亚洲心脏病医院心外科
基金项目:武汉市卫生健康委员会科研基金(WX17D44)。
摘    要:
目的评估经皮腔内肺动脉成形术(PTPA)治疗慢性血栓栓塞性肺动脉高压(CTEPH)患者的有效性和安全性。方法该研究为前瞻性单臂试验。纳入2017年1月至2019年6月武汉亚洲心脏病医院心外科确诊的CTEPH患者。以明确诊断CTEPH的时间为基线, 收集入选患者的基线临床资料, 包括年龄、性别、世界卫生组织(WHO)功能分级、6 min步行距离、N末端B型利钠肽原(NT-proBNP)水平以及右心导管测定的血流动力学指标等。患者分次行PTPA, 统计每位患者扩张血管数, 术后24周随访并复查右心导管。记录手术安全性指标, 包括全因死亡、围术期并发症、再灌注肺水肿等。结果共入选患者19例, 年龄(56.3±12.5)岁, 男性7例。入选患者分别进行了1~7次PTPA, 总计56次, 累计扩张肺动脉260支, 每次扩张血管(5.14±2.36)支。共13例患者测定了6 min步行距离, 为(307±130)m。入选患者PTPA术后均自述体力明显改善, 尤其以第一次手术后为著。PTPA术后24周, 入选患者平均肺动脉压由基线的(40.11±7.55)mmHg(1 mmHg=0.133 kPa)...

关 键 词:高血压, 肺性  治疗结果  经皮腔内肺动脉成形术

Efficacy and safety of percutaneous transluminal pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension
Jin Bowen,Zhang Gangcheng,Shen Qunshan,Long Kai. Efficacy and safety of percutaneous transluminal pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension[J]. Chinese Journal of Cardiology, 2022, 0(1): 49-54
Authors:Jin Bowen  Zhang Gangcheng  Shen Qunshan  Long Kai
Affiliation:(Department of Cardiovascular Surgery,Wuhan Asia Heart Hospital,Wuhan 430000,China)
Abstract:
Objective To explore the efficacy and safety of percutaneous transluminal pulmonary angioplasty(PTPA)in patients with chronic thromboembolic pulmonary hypertension(CTEPH).Methods This prospective single arm study included 19 CTEPH patients(7 male,age(56.3±12.5)years)admitted to Wuhan Asia Heart Hospital from January 2017 to June 2019 and received PTPA interventional therapy.Baseline data,including age,sex,WHO functional class,6-minute walk distance(6MWD),NT-proBNP,right heart catheterization values,were collected.Patients received single or repeated PTPA.Number of dilated vessels from each patient was analyzed,patients were followed up for 24 weeks and right heart catheterization was repeated at 24 weeks post initial PTPA.All-cause death,perioperative complications,and reperfusion pulmonary edema were reported.WHO functional class,6MWD,NT-proBNP,right heart catheterization values were compared between baseline and at 24 weeks follow up.Results Nineteen CTEPH patients received a total of 56 PTPA treatments.The pulmonary artery pressure(mPAP)decreased from(40.11±7.55)mmHg(1 mmHg=0.133 kPa)to(27.53±4.75)mmHg(P<0.001),and the total pulmonary resistance(TPR)decreased from(13.00±3.56)Wood U to(5.48±1.56)Wood U(P<0.001),cardiac output increased from(3.19±0.63)L/min to(5.23±0.94)L/minutes(P<0.01)at 24 weeks post PTPA.The WHO functional class improved significantly(P<0.001),6MWD increased from(307.08±129.51)m to(428.00±112.64)m(P=0.002),the NT-proBNP decreased at 24 weeks post PTPA(P=0.002).During the follow-up period,there was no death;hemoptysis occurred in 4 patients during the operation,none of which resulted in serious adverse clinical consequences.One patient developed reperfusion pulmonary edema and recovered after treatment.Conclusion PTPA treatment is safe and can significantly improve the hemodynamics and WHO functional class of patients with CTEPH.
Keywords:Hypertension,pulmonary  Treatment outcome  Percutaneous transluminal pulmonary angioplasty
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号